<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399657</url>
  </required_header>
  <id_info>
    <org_study_id>EXTINCT</org_study_id>
    <nct_id>NCT02399657</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema</brief_title>
  <official_title>A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single Arm, Single Dose Study to Evaluate the Effect of intravitreal dexamethasone implant
      (Ozurdex®) on hard exudates of diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular edema (DME) is important vision threatening complication of diabetes
      mellitus. Laser photocoagulation, vitrectomy, intravitreal steroid injection and intravitreal
      antiVEGF (anti vascular endothelial growth factor) injection are being used as treatment of
      DME. Sustained releasing intravitreal dexamethasone implant has been known to be effective in
      reducing the central retinal thickness and gain of vision for DME. Although hard exudate at
      macula is important pathology of DME, impact of intravitreal dexamethasone implant on hard
      exudate are not studied yet. Therefore the investigators designed the descriptive study to
      reveal the hard exudate change in DME eyes treated with intravitreal dexamethasone implant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center)</measure>
    <time_frame>after 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average change in ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Ratio of eyes with central macular thickness under 290 micrometer in OCT (optical coherence tomography)</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Ratio of eyes showing reduced perifoveal capillary leakage in fluorescein angiography</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average change in number of microaneurysm in macula</measure>
    <time_frame>after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progression rate of cataract</measure>
    <time_frame>for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes having increased intraocular pressure</measure>
    <time_frame>for 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Macular Edema</condition>
  <condition>Retinal Exudates and Deposits</condition>
  <arm_group>
    <arm_group_label>Intravitreal dexamethasone implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal dexamethasone 0.7mg implant (Ozurdex)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal dexamethasone 0.7mg implant</intervention_name>
    <description>Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata</description>
    <arm_group_label>Intravitreal dexamethasone implant</arm_group_label>
    <other_name>Ozurdex injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with CSME (clinically significant macular edema) with hard exudates
             within 1500 micrometer from foveal center

          2. Those who have a BCVA (best corrected visual acuity) of study eye between 0.06(20/320)
             and 0.5(20/40)

          3. Those who have a central macular thickness on OCT over 300 micrometer

          4. If both eyes are eligible, eye having more hard exudates is selected (contralateral
             eye should be treated with corticosteroid other than Ozurdex or focal laser
             photocoagulation, anti-VEGF (vascular endothelial growth factor) injection is not
             allowed in contralateral eye)

        Exclusion Criteria:

          1. Those who have CSME without hard exudates

          2. Those who have macular edema not related with diabetic retinopathy (e.g. AMD
             (age-related macular degeneration), uveitis, retinal vein occlusion and untreated
             malignant hypertension)

          3. Those who have a history of Intraocular surgery (e.g. cataract surgery) within 3
             months

          4. Those who have a visual acuity of contralateral eye less than 0.1 (10/100)

          5. Those who received focal laser treatment on macula within 3 months

          6. Those who had intravitreal anti-VEGF agent injection within 3 months

          7. Those who had intravitreal triamcinolone injection within 6 months

          8. Those who have other ophthalmologic disease affecting visual acuity (e.g. central
             corneal opacity, cataract change at lens center)

          9. Those who have severe systemic disease (e.g. uncontrolled DM, hypertension,
             cardiovascular disease, cerebrovascular disease)

         10. Those who refuse to submit written consent

         11. Those who cannot understand the contents of the clinical study and cooperate in the
             clinical trial

         12. Those who are pregnant or lactating women

         13. Those who have a history of vitrectomy

         14. Those who require systemic corticosteroid or immunosuppressive agent treatment

         15. Those who are banned from using Ozurdex

               -  Ocular infection or periocular infection

               -  Advanced glaucoma

               -  Hypersensitivity to dexamethasone or other component of Ozurdex

               -  Posterior lens capsule rupture or Aphakia

               -  Anterior chamber intraocular lens or posterior capsule rupture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Woong Kim, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji Eun Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo Eun Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Jin Jeung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Joon Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosin University Gospel Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In Young Chung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Pil Shin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Hyok Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Woong Kim, M.D.</last_name>
    <phone>82-51-890-8997</phone>
    <email>maekbak@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chang Ki Yoon, M.D.</last_name>
    <phone>82-51-890-8707</phone>
    <email>syst18@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnam-do</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Young Chung, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Joon Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Jin Jeung, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan national university hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Eun Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Eun Lee, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Woong Kim, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Pil Shin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Hyok Chang, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001. Review.</citation>
    <PMID>19171208</PMID>
  </reference>
  <reference>
    <citation>Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995 Jan;102(1):7-16.</citation>
    <PMID>7831044</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.</citation>
    <PMID>2866759</PMID>
  </reference>
  <reference>
    <citation>Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010 Mar;128(3):289-96. doi: 10.1001/archophthalmol.2010.21.</citation>
    <PMID>20212197</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Hyun Woong Kim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>macular edema</keyword>
  <keyword>hard exudate</keyword>
  <keyword>intravitreal injections</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

